Beacon Pharmaceuticals PLC
DDSE:BEACONPHAR96.10
BDT
-0.60
(-0.62%)
ISIN
BD0482BECON5
Return %
Stock
S&P 500
1Y
-5.23
14.20
3Y
-60.78
81.12
5Y
-55.69
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Ulfat Karim
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Jun 20, 2010
- Website
- beaconpharma.com.bd
- Similar Companies
- Business
- Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical and biotechnology company engaged in the development, manufacturing, marketing, and international distribution of generic prescription drugs, biotechnology formulations, and specialized oncology therapeutics. Founded in 2006 and headquartered in Dhaka, Bangladesh, the company operates modern manufacturing facilities situated in Bhaluka, Mymensingh, designed in accordance with global regulatory standards including WHO-cGMP, US FDA, UK MHRA, and TGA Australia guidelines. Beacon Pharmaceuticals provides a broad therapeutic portfolio comprising specialized oncology and hematology treatments, including conventional chemotherapeutic agents, oral targeted kinase inhibitors, monoclonal antibodies, and supportive care therapeutics; biotechnology and biosimilar formulations, including recombinant proteins and therapeutic peptides; systemic anti-infectives, including dedicated cephalosporin antibiotics available in oral tablets, capsules, dry syrups, and sterile injectable presentations; chronic care pharmaceuticals, covering cardiovascular drugs, antihypertensives, lipid-lowering agents, anticoagulants, and antidiabetics; gastrointestinal and central nervous system therapeutics, including proton pump inhibitors, analgesics, antiemetics, and neurological therapies; and specialized hospital care products, including lyophilized vials, sterile liquid injectables, respiratory preparations, and nutritional supplements. The company distributes its products domestically to healthcare institutions, retail pharmacies, and hospitals across Bangladesh, while maintaining an active international presence by exporting pharmaceutical products to more than 140 countries across Asia, Africa, Europe, the Middle East, and Latin America. In recent developments, Beacon Pharmaceuticals has expanded its global export distribution network into new emerging markets, enhanced its specialized biotherapeutic and oncology pipeline through the launch of advanced generic molecular therapies, expanded manufacturing and lyophilization capacity at its Bhaluka production campus, established strategic healthcare Memorandums of Understanding to broaden patient access to critical therapies, and implemented operational optimization measures that contributed to substantial top-line revenue and net profit growth.